Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023

November 6, 2023 —  Bristol Myers Squibb  announced that research across the company’s cardiovascular franchise will be presented at the American Heart Association’s (AHA) annual Scientific Sessions, taking place November 11-13, 2023 in Philadelphia, Pennsylvania. Clinical trial data to be featured include new analyses of the effectiveness of CAMZYOS (mavacamten) in patients with and without gene variants from the Phase 3 EXPLORER-HCM study, as well as new real-world analyses of patients with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) receiving CAMZYOS in clinical practice. 

The Bristol Myers Squibb-Pfizer Alliance will also provide new data describing disparity in oral anticoagulant utilization patterns among commercially insured patients with non-valvular atrial fibrillation (NVAF) with high stroke risk by geographic region and race in the U.S.

“We’re looking forward to the opportunity to showcase new clinical and real-world analyses across our cardiovascular franchise, which support our commitment to develop medicines that address the global burden of cardiovascular disease,” said Roland Chen, Senior Vice President, Head of Development, Immunology, Cardiovascular & Neurology. “These data at the AHA Scientific Sessions continue to demonstrate the benefit that treatment with CAMZYOS provides for a broad spectrum of patients with symptomatic obstructive hypertrophic cardiomyopathy in clinical studies as well as in clinical practice.”  

Key presentations include: 

• An exploratory subgroup analysis of the Phase 3 EXPLORER-HCM study analyzing treatment effectiveness with CAMZYOS for patients with and without sarcomere gene variants. 
• Findings from an analysis of an EXPLORER-HCM study assessing the relationship between patient-reported KCCQ and physician-assessed NYHA class to enhance understanding of KCCQ scores and aid shared decision-making process of patients and physicians in clinical practice. 
• A retrospective cohort study of claims data from commercial specialty pharmacies demonstrating high real-world adherence to CAMZYOS in >600 patients with symptomatic obstructive HCM in the United States. 
• An analysis of Medicare claims data from 2016 to 2020 investigating evidence of diagnosis-related disparities in patients over 65 with HCM specifically relating to race/ethnicity and county-level disparities. 

Summary of Presentations

Select Bristol Myers Squibb and Bristol Myers Squibb-Pfizer Alliance studies at AHA Congress 2023 include: 



For more information: https://www.bms.com/ 

Find more AHA23 conference coverage here